Genetic Technologies Limited
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more
Genetic Technologies Limited (GNTLF) - Total Liabilities
Latest total liabilities as of December 2024: $3.92 Million USD
Based on the latest financial reports, Genetic Technologies Limited (GNTLF) has total liabilities worth $3.92 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genetic Technologies Limited - Total Liabilities Trend (2000–2024)
This chart illustrates how Genetic Technologies Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genetic Technologies Limited Competitors by Total Liabilities
The table below lists competitors of Genetic Technologies Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Methanor
PA:ALMET
|
France | €35.87K |
|
Pacific Ridge Exploration Ltd
OTCQB:PEXZF
|
USA | $389.75K |
|
Seko S.A.
WAR:SEK
|
Poland | zł39.60 Million |
|
Kun Peng International Ltd.
OTCQB:KPEA
|
USA | $9.03 Million |
|
Centrex Ltd
AU:CXM
|
Australia | AU$34.09 Million |
|
Magna Polonia SA
WAR:06N
|
Poland | zł7.22 Million |
|
APXIF
PINK:APXIF
|
USA | $9.91 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Genetic Technologies Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genetic Technologies Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genetic Technologies Limited (2000–2024)
The table below shows the annual total liabilities of Genetic Technologies Limited from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | $4.36 Million | +17.93% |
| 2023-06-30 | $3.69 Million | -15.49% |
| 2022-06-30 | $4.37 Million | +203.80% |
| 2021-06-30 | $1.44 Million | -12.30% |
| 2020-06-30 | $1.64 Million | +9.81% |
| 2019-06-30 | $1.49 Million | +2.73% |
| 2018-06-30 | $1.45 Million | -4.91% |
| 2017-06-30 | $1.53 Million | +8.73% |
| 2016-06-30 | $1.41 Million | -20.11% |
| 2015-06-30 | $1.76 Million | -64.08% |
| 2014-06-30 | $4.90 Million | +91.38% |
| 2013-06-30 | $2.56 Million | +25.61% |
| 2012-06-30 | $2.04 Million | -3.28% |
| 2011-06-30 | $2.11 Million | -17.70% |
| 2010-06-30 | $2.56 Million | -46.51% |
| 2009-06-30 | $4.79 Million | +44.42% |
| 2008-06-30 | $3.32 Million | -18.12% |
| 2007-06-30 | $4.05 Million | -3.01% |
| 2006-06-30 | $4.18 Million | -35.85% |
| 2005-06-30 | $6.51 Million | +22.35% |
| 2004-06-30 | $5.32 Million | +79.25% |
| 2003-06-30 | $2.97 Million | +59.17% |
| 2002-06-30 | $1.86 Million | +15.24% |
| 2001-06-30 | $1.62 Million | +27.42% |
| 2000-06-30 | $1.27 Million | -- |